Need advice in managing cancer immunotherapy cardiotoxicity?

Request Assistance

FDA Public Workshop: Assessment of Cardiovascular Toxicities in Immuno-oncology Trials
Posted by Moslehi on January 22, 2018

On Friday, December 1, 2017, the U.S. Food & Drug Administration (FDA) announced a public workshop entitled, “Assessment of Cardiovascular Toxicities in Immuno-oncology Trials”. This workshop provided a forum for discussion of cardiovascular toxicities in immuno-oncology clinical trials. The workshop focused on the identification...

Read More
Manuscripts published in Circulation raise awareness for immune checkpoint inhibitor associated myocarditis
Posted by Moslehi on January 22, 2018

Two manuscripts published on November 21, 2017 of the journal Circulation bring additional awareness for the syndrome of immune checkpoint-inhibitor (ICI)-associated myocarditis. Thuny and colleagues (Hospital Nord, Marseille, France) present a case series of 30 patients with ICI-induced cardiotoxicity. Cardiotoxicity was diagnosed at a...

Read More
Cardio-Oncology highlighted at American Heart Association Annual Meeting 2017
Posted by Moslehi on January 22, 2018

There were several cardio-oncology sessions at the American Heart Association (AHA) annual meeting which occurred in November 2017 in Anaheim, California. A session called “The Emerging Science of Cardio-Oncology” focused on the rapidly evolving area of clinical practice in cancer patients with heart failure or acute coronary...

Read More
View All
connect with us

Thanks to everyone for participating in an awesome annual scientific meeting. Can’t wait to do it again in 2019 in Philadelphia!

Best Ways to Identify Myocarditis in Cancer Patients

Great tribute to seminal work done by Dr. Doug Mann @WashU_cards on the “cytokine hypothesis” in HF by @DukeHFDoc #HFSA2018 @HFSA but does targeting cytokines work in the clinic? @johnmcph @yaleHFdoc

Very intriguing talk by @JJheart_doc on targeting “inflammatory” markers for the treatment of heart failure #HFSA2018 Have to be specific with what we use & when...MCP to target galectin-3 for A subset of HF? @DukeHFDoc @HFSA